STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GPCR STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

Closed 01-15 16:00:00 EST

85.02

+0.69

+0.82%

盘后90.99

+5.97+7.02%

19:59 EST

High85.39	Low80.85	Vol1.02M
Open83.66	D1 Closing84.33	Amplitude5.38%
Mkt Cap5.88B	Tradable Cap4.17B	Total Shares69.14M
T/O85.78M	T/O Rate2.09%	Tradable Shares49.03M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":85.02,"timestamp":1768510800000,"preClose":84.33,"halted":0,"volume":1024059,"hourTrading":{"tag":"盘后","latestPrice":90.99,"preClose":85.02,"latestTime":"19:59 EST","volume":74117,"amount":6581010.0028,"timestamp":1768525189123},"delay":0,"floatShares":49026700,"shares":69139200,"eps":-3.652895,"marketStatus":"Closed","change":0.69,"latestTime":"01-15 16:00:00 EST","open":83.66,"high":85.39,"low":80.85,"amount":85775535.140355,"amplitude":0.053836,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.652895,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768554000000},"marketStatusCode":5,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":84.33,"preHourTrading":{"tag":"盘前","latestPrice":83.71,"preClose":84.33,"latestTime":"09:29 EST","volume":2065,"amount":175600.06275,"timestamp":1768487397022},"postHourTrading":{"tag":"盘后","latestPrice":90.99,"preClose":85.02,"latestTime":"19:59 EST","volume":74117,"amount":6581010.0028,"timestamp":1768525189123},"volumeRatio":0.646724,"impliedVol":0.7869,"impliedVolPercentile":0.5418},"requestUrl":"/m/hq/s/GPCR/wiki","defaultTab":"wiki","newsList":[{"id":"1173873969","title":"24H | Springview Rockets Another 16% After a 674% Rally; GPCR Jumps 6% as It Expects Pills to Capture up to 50% of GLP-1 Obesity Market; Hesai Gains 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173873969","media":"Tiger Newspress","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173873969?lang=en_us&edition=fundamental","pubTime":"2026-01-16 09:55","pubTimestamp":1768528535,"startTime":"0","endTime":"0","summary":"$Structure Therapeutics(GPCR)$ stock jumped about 6% in overnight trading as its CEO expects oral weight-loss pills to capture as much as half of the GLP-1 market by 2030, driven partly by pent-up...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","HSAI","SPHL"],"gpt_icon":0},{"id":"2603984562","title":"Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2603984562","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603984562?lang=en_us&edition=fundamental","pubTime":"2026-01-16 00:07","pubTimestamp":1768493220,"startTime":"0","endTime":"0","summary":"Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its experimental pill to market.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/15/Woman-Stepping-On-Floor-Scale-And-Measur.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/15/Woman-Stepping-On-Floor-Scale-And-Measur.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/49940898/structure-therapeutics-ceo-says-compounding-threat-looms-for-future-obesity-treatments","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/01/49940898/structure-therapeutics-ceo-says-compounding-threat-looms-for-future-obesity-treatments","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IE00BZ1G4Q59.USD","LU2471134523.USD","LU0256863811.USD","LU0432979614.USD","LU2746668974.SGD","LU2237443895.HKD","LU2237443465.HKD","LU2265009873.SGD","LU0640476718.USD","LU1917777945.USD","LU2112291526.USD","LU0708995401.HKD","LU1057294990.SGD","LU0106261372.USD","LU0238689110.USD","LU0385154629.USD","LU2471134796.USD","LU1127390331.HKD","IE0002141913.USD","IE00BKPKM429.USD","LU0823416689.USD","LU1551013425.SGD","SG9999017495.SGD","LU0061475181.USD","LU1868837136.USD","LU1280957306.USD","BK4599","LU0114720955.EUR","LU2750360997.AUD","IE00B2B36J28.USD","SG9999013999.USD","LU1548497426.USD","LU0203201768.USD","IE00BJJMRZ35.SGD","LU1974910355.USD","LU0943347566.SGD","LU2552382132.HKD","LU1720051017.SGD","LU2108987350.USD","GPCR","LU1069344957.HKD","LU1267930730.SGD","LU0456855351.SGD","IE0004445239.USD","BK4534","LU2746668461.USD","IE00B7KXQ091.USD","LU1868836757.USD","LU0225283273.USD","LU0820561909.HKD","LU2168564065.EUR","GB00BDT5M118.USD","LU2237443622.USD","IE00BKDWB100.SGD","LU2360106947.USD","LU1989771016.USD","LU0058720904.USD","LU0097036916.USD","LU2471134879.HKD","LU2236285917.USD","LU1023059063.AUD","IE00BFSS7M15.SGD","LU0353189763.USD","IE00BJJMRY28.SGD","LU0198837287.USD","LU2471134952.CNY","LU1868837300.USD","LU1623119135.USD","IE00BK4W5M84.HKD","LU0320765992.SGD","BK4585","LU1093756168.USD","LU1323610961.USD","LU0154236417.USD","LU2461242641.AUD","LU0786609619.USD","LU1366192091.USD","SG9999014914.USD","IE00BJT1NW94.SGD","LU0823434740.USD","LU0256863902.USD","LU2602419157.SGD","LU0683600562.USD","LU0320765059.SGD","BK4581","LU0323591593.USD","LU0109391861.USD","IE00B1BXHZ80.USD","LU0094547139.USD","LU1035775433.USD","SG9999001176.SGD","LU0882574055.USD","LU2552382215.SGD","IE0009355771.USD","LU2168563687.JPY","IE00B4R5TH58.HKD","LU2237438978.USD","SG9999014898.SGD","LU2361044949.HKD","LU2106854487.HKD","IE00BK4W5L77.USD","LU0823434583.USD","LU2168564495.EUR","LU1868836591.USD","LU0889565916.HKD","LU0471298777.SGD","LU0820561818.USD","IE00BFSS8Q28.SGD","LU2023250504.SGD","LU2417539215.USD","SGXZ57979304.SGD","IE00BWXC8680.SGD","LU1814569148.SGD","IE00BFTCPJ56.SGD","SG9999015978.USD","LU1868836914.USD","SG9999014906.USD","LU0109394709.USD","LU1232071149.USD","LU1712237335.SGD","IE00B4JS1V06.HKD","IE0004445015.USD","IE00B1XK9C88.USD","SG9999014880.SGD","LU2357305700.SGD","LU2264538146.SGD","LU2237443549.SGD","LU2089984988.USD","LU1064131342.USD","SGXZ81514606.USD","LU0787776722.HKD","LU2491050071.SGD","SG9999015952.SGD","LU2491050154.USD","BK4007","BK4539","SGXZ51526630.SGD","LU0466842654.USD","SG9999001176.USD","LU2361045086.USD","BK4533","SG9999015986.USD","SGXZ31699556.SGD","LU2462157665.USD","BK4516","BK4139","LU1720051108.HKD","LU1093756325.SGD","IE00BJLML261.HKD","IE00BJJMRX11.SGD","LU2087625088.SGD","LU0316494557.USD","LU0417517546.SGD","LU0266013472.USD","LU2168564149.EUR","LU2456880835.USD","LU0203202063.USD","BK4588","LU1988902786.USD","IE0005OL40V9.USD","LU1551013342.USD","LU0882574139.USD","LU2237443382.USD","IE00BKVL7J92.USD","LU0234572021.USD","LU2324357040.USD","SG9999015945.SGD","LU0471298694.HKD","LU1061106388.HKD","LU0689472784.USD","LU2063271972.USD","LU0079474960.USD","BK4532","LU0289739699.SGD","LU1291159041.SGD","LU0006306889.USD","SG9999018857.SGD","LU2168564222.USD","SGXZ99366536.SGD","LU0672654240.SGD","LU2491049909.HKD","LU0122379950.USD","LU0353189680.USD","IE00BN29S564.USD","LU2750360641.GBP","LU1983299246.USD","LU2237443978.SGD","LU2211815571.USD","LU2468319806.SGD","LU0096364046.USD","LU2552382058.USD","LU1804176565.USD","SG9999018865.SGD","LU2361044865.SGD","LU0354030438.USD","IE00B775H168.HKD","LU0354030511.USD"],"gpt_icon":0},{"id":"1166908326","title":"Structure Therapeutics CEO Voices Concerns Over Generic Competition for Weight-Loss Drugs: Challenges Loom Even Before Market Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1166908326","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166908326?lang=en_us&edition=fundamental","pubTime":"2026-01-15 15:07","pubTimestamp":1768460825,"startTime":"0","endTime":"0","summary":"The CEO of Structure Therapeutics (GPCR.US), Raymond Stevens, expressed in an interview at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday that although the company's experimental...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4007","GPCR"],"gpt_icon":0},{"id":"2603964415","title":"Structure expects pills to capture up to 50% of GLP-1 obesity market by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2603964415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603964415?lang=en_us&edition=fundamental","pubTime":"2026-01-15 04:56","pubTimestamp":1768424188,"startTime":"0","endTime":"0","summary":"UPDATE 1-Structure expects pills to capture up to 50% of GLP-1 obesity market by 2030Adds details from the interview throughout, background in paragraph 7By Maggie Fick, Sabrina Valle and Puyaan Singh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nL4N3YF1UE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2461242641.AUD","LU0882574139.USD","IE00BJT1NW94.SGD","LU2602419157.SGD","LU1883839398.USD","LU2106854487.HKD","LU0320765059.SGD","IE00B19Z3581.USD","LU1066053197.SGD","LU0689472784.USD","SG9999014906.USD","IE0009355771.USD","LU1712237335.SGD","LU0683600562.USD","LU2471134796.USD","LU0079474960.USD","LU2237443465.HKD","LU2417539215.USD","LU0198837287.USD","LU0323591593.USD","LU2168564149.EUR","LU0823416689.USD","LU1988902786.USD","LU0466842654.USD","LU2471134879.HKD","LU2265009873.SGD","LU1366192091.USD","LU1323610961.USD","SG9999011175.SGD","LU0238689110.USD","LU2491050154.USD","LU1720051017.SGD","LU0320765992.SGD","LU0256863811.USD","LU1720051108.HKD","LU2361045086.USD","LU2468319806.SGD","BK4568","LU0823434583.USD","LU0354030438.USD","LU1868837300.USD","LU0225283273.USD","LU0353189680.USD","LU2237438978.USD","IE00BFTCPJ56.SGD","IE00BWXC8680.SGD","LU0225771236.USD","LU2491050071.SGD","IE0002141913.USD","LU0787776722.HKD","LU1057294990.SGD","IE0002270589.USD","IE00B2B36J28.USD","IE00BFSS8Q28.SGD","LU0203201768.USD","LU2108987350.USD","SG9999018865.SGD","LU2237443622.USD","IE00B7KXQ091.USD","LU2360106947.USD","IE00BLSP4239.USD","GB00BDT5M118.USD","LU2237443895.HKD","IE00BKDWB100.SGD","SG9999014898.SGD","LU2168564495.EUR","LU2462157665.USD","LU0820561818.USD","LU2552382058.USD","LU0061475181.USD","IE00BFSS7M15.SGD","LU0109391861.USD","LU1551013425.SGD","SG9999001176.SGD","SGXZ57979304.SGD","LU0672654240.SGD","LU1894683264.USD","LU1623119135.USD","LU1983299246.USD","LU1551013342.USD","LU2112291526.USD","LU0106261372.USD","LU1868837136.USD","LU0266013472.USD","SG9999002224.SGD","BK4599","LU0256863902.USD","LU2237443549.SGD","LU2237443978.SGD","IE00B1BXHZ80.USD","LU1804176565.USD","LU0417517546.SGD","SG9999014880.SGD","BK4550","BK4516","LU1868836591.USD","LU2746668461.USD","SG9999003800.SGD","SG9999001176.USD","GPCR","IE00BBT3K403.USD","LU0109394709.USD","IE00B1XK9C88.USD","LU0321505439.SGD","LU1232071149.USD","LU1548497426.USD","IE00B19Z3B42.SGD","SG9999014914.USD","LU2552382215.SGD","IE00BK4W5M84.HKD","LU2023250504.SGD","LU1061106388.HKD","LU2750360641.GBP","LU2211815571.USD","LU1064131342.USD","BK4007","LU2471134952.CNY","SG9999015986.USD","LU2361044865.SGD","LU1894683348.USD","BK4585","LU1868836914.USD","BK4588","IE00BN29S564.USD","LU0820561909.HKD","LU0097036916.USD","LU0114720955.EUR","LU0170899867.USD","BK4592","LU0306806265.USD","LU2168564222.USD","IE00BJJMRX11.SGD","SG9999017495.SGD","LU0354030511.USD","IE0004445239.USD","IE00BLSP4452.SGD","BK4581","LU2746668974.SGD","LU0316494557.USD","LU0058720904.USD","LU1023059063.AUD","LU1974910355.USD","LU2456880835.USD","LU0006306889.USD","LU0353189763.USD","LU1066051498.USD","SGXZ31699556.SGD","IE00BKPKM429.USD","LU1814569148.SGD","IE00BJJMRY28.SGD","LU0708995401.HKD","LU0868494617.USD","LU1280957306.USD","LU0471298777.SGD","IE00BJJMRZ35.SGD","LU0122379950.USD","LU0225284248.USD","LU0096364046.USD","LU2357305700.SGD","LU0094547139.USD","LU2491049909.HKD","LU2168563687.JPY","LU2237443382.USD","LU0234572021.USD","IE00B4R5TH58.HKD","IE0005OL40V9.USD","LU2264538146.SGD","LU0289739699.SGD","IE0004445015.USD","LU0306807586.USD","LU1069344957.HKD","LU2063271972.USD","LU0471298694.HKD","LU1291159041.SGD","LU2552382132.HKD","SG9999018857.SGD","BK4533","BK4534","IE000M9KFDE8.USD","LU0432979614.USD","LU1868836757.USD","LU0456855351.SGD","LU0321505868.SGD","LU2087625088.SGD","LU2324357040.USD","SG9999013999.USD","LU0640476718.USD","SG9999015978.USD","LU0889565916.HKD","SG9999015945.SGD","IE00BK4W5L77.USD","LU1127390331.HKD","LU1093756168.USD","LU2471134523.USD","SGXZ81514606.USD","LU2236285917.USD","LU0882574055.USD","LU2750360997.AUD","LU2168564065.EUR","LU1917777945.USD","LU1035775433.USD","LU0985481810.HKD","IE00B775H168.HKD","IE00BJLML261.HKD","LU2089984988.USD","LU0786609619.USD","LU0203202063.USD","LU0385154629.USD","SGXZ99366536.SGD","SGXZ51526630.SGD","SG9999002232.USD","LU2361044949.HKD","LU0943347566.SGD","LU1093756325.SGD","IE00B4JS1V06.HKD","LU0823434740.USD","LU1989771016.USD","LU1267930730.SGD","SG9999015952.SGD"],"gpt_icon":0},{"id":"2603641584","title":"Structure Therapeutics CEO Expects Pills to Capture 25% to 50% of Glp-1 Weight-Loss Market by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2603641584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603641584?lang=en_us&edition=fundamental","pubTime":"2026-01-15 03:37","pubTimestamp":1768419455,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nFWN3YF1T4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2603100641","title":"Structure Therapeutics CEO Says Strategic Partner for Commercialization of Its Medicine Needs to Have Strong Relationships With Primary Care Doctors","url":"https://stock-news.laohu8.com/highlight/detail?id=2603100641","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603100641?lang=en_us&edition=fundamental","pubTime":"2026-01-15 03:37","pubTimestamp":1768419455,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nFWN3YF1T4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GPCR","BK4007","BK4599"],"gpt_icon":0},{"id":"2603896637","title":"What to Watch in the Day Ahead - Wednesday, January 14","url":"https://stock-news.laohu8.com/highlight/detail?id=2603896637","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603896637?lang=en_us&edition=fundamental","pubTime":"2026-01-14 03:31","pubTimestamp":1768332717,"startTime":"0","endTime":"0","summary":"What to Watch in the Day Ahead - Wednesday, January 14The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ah","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nL6N3YE19H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU0345769631.USD","BAC","LU0265550359.USD","LU1551013425.SGD","GPCR","LU0820562030.AUD","LU0130517989.USD","BK4559","BK4553","LU1506573853.SGD","LU0162691827.USD","LU0114720955.EUR","LU0985481810.HKD","LU2265009873.SGD","LU2552382058.USD","LU2129689514.USD","LU2360032135.SGD","LU1244550577.SGD","LU0345770308.USD","LU0061475181.USD","LU1868837136.USD","LU2236285917.USD","LU0868494708.USD","LU1868836591.USD","LU1974910355.USD","LU2237443978.SGD","LU0170899867.USD","LU2023250843.SGD","BK4588","LU2237443895.HKD","LU2361045086.USD","LU1670710661.SGD","LU1894683348.USD","LU0237698245.USD","LU0208291251.USD","LU0098860793.USD","IE00BSNM7G36.USD","LU0306806265.USD","LU0708994859.HKD","LU1267930227.SGD","LU2054465674.USD","LU1720051017.SGD","LU1720051108.HKD","LU0321505868.SGD","IE00BYXW3230.USD","LU1814569148.SGD","BMY","LU0320765489.SGD","LU2461242641.AUD"],"gpt_icon":0},{"id":"2603763977","title":"Structure Therapeutics rises 14.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603763977","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603763977?lang=en_us&edition=fundamental","pubTime":"2026-01-14 01:05","pubTimestamp":1768323946,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) is up 14.1%, or $9.79 to $79.15. Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-rises-14-1-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-rises-14-1-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4599","LENZ","BK4539","BK4007","GPCR"],"gpt_icon":0},{"id":"2603523949","title":"What to Watch in the Day Ahead - Tuesday, January 13","url":"https://stock-news.laohu8.com/highlight/detail?id=2603523949","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603523949?lang=en_us&edition=fundamental","pubTime":"2026-01-13 03:30","pubTimestamp":1768246210,"startTime":"0","endTime":"0","summary":"What to Watch in the Day Ahead - Tuesday, January 13The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL6N3YD0VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4008","LU1914381329.SGD","LU0683600562.USD","LU1720051108.HKD","LU0689472784.USD","LU1917777945.USD","LU1244550221.USD","LU1894683348.USD","LU0211328371.USD","IE00BDRTCR15.USD","IE00BBT3K403.USD","LU0868494617.USD","LU0345769631.USD","LU1116320901.HKD","LU2237443978.SGD","LU2023250843.SGD","LU2236285917.USD","BK4533","GPCR","LU2213496289.HKD","LU1496350171.SGD","LU0203345920.USD","IE00BDCRKT87.USD","LU2237443622.USD","LU1084165304.USD","LU1244550494.USD","IE00BZ1G4Q59.USD","LU0208291251.USD","LU1280957306.USD","DAL","LU0256863811.USD","BK4500","BK4566","IE00B1XK9C88.USD","LU1064131342.USD","LU0868494708.USD","LU2054465674.USD","IE00BYXW3230.USD","BK4207","LU0251132253.USD","LU1670627923.USD","LU0787776722.HKD","LU1145028129.USD","LU0048584097.USD","LU0265550359.USD","LU0234572021.USD","LU1894683264.USD","LU0211331839.USD","IE00BJLML261.HKD","LU1496350502.SGD"],"gpt_icon":0},{"id":"2603424785","title":"Funding for Risky Biotechs Is Returning -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2603424785","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603424785?lang=en_us&edition=fundamental","pubTime":"2026-01-13 01:00","pubTimestamp":1768237200,"startTime":"0","endTime":"0","summary":"Wall Street is opening its coffers again for risky drug developers.Many small biotechnology companies have struggled to raise money in recent years. Public markets were all but shut. Initial public offerings slowed to a trickle and follow-on share sales, used by already-public companies to raise more funding, were muted. Some biotechs shut down.Yet investors began writing more checks toward the end of last year, giving some firms much-needed funding to pay for their costly research.Drug developers and other life-sciences companies traded on U.S. exchanges raised more than $13 billion from issuing new stock in the fourth quarter, the most for any quarter since the second quarter of 2021, according to data from LSEG, a financial-data provider.Apogee Therapeutics, which is developing treatments for immune diseases, raised some $345 million from investors in October, more than its $300 million target.Funding is crucial for startups. They are often years away from producing any revenue from","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","BK4007","GPCR","APGE","BK4585","BK4505","BK4588","BK4139","BK4599","DYN"],"gpt_icon":0},{"id":"2603928544","title":"Structure Therapeutics Inc. unveils oral obesity treatment pipeline in new corporate presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603928544","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603928544?lang=en_us&edition=fundamental","pubTime":"2026-01-13 00:05","pubTimestamp":1768233951,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc. released a corporate presentation detailing its current approach and pipeline in the development of oral small molecule treatments for obesity and related metabolic conditions. The company highlighted the significant unmet need for accessible obesity treatments worldwide, noting that current injectable GLP-1 therapies address less than 5% of the potential market in the United States. Structure Therapeutics is advancing several oral small molecule candidates, including the GLP-1 receptor agonist Aleniglipron, which is Phase 3 ready, and two amylin candidates  in early-stage clinical development. The presentation emphasized the pharmacologic and economic advantages of oral small molecules over oral peptides, including ease of administration, combination potential, scalability, and cost benefits. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. W","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL8pb19B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2602130545","title":"Septerna to Present GPCR Pipeline Updates at JPM Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602130545","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602130545?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:13","pubTimestamp":1768227190,"startTime":"0","endTime":"0","summary":"An update from Septerna, Inc. ( ($SEPN) ) is now available. Septerna announced that during the week of January 12, 2026 it will meet investors and ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/septerna-to-present-gpcr-pipeline-updates-at-jpm-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/septerna-to-present-gpcr-pipeline-updates-at-jpm-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1162221912.USD","LU0211328371.USD","LU2213496289.HKD","LU2756315318.SGD","LU2462157665.USD","IE00B3S45H60.SGD","SG9999002224.SGD","IE00B1XK9C88.USD","SEPN","LU1670627923.USD","BK4599","IE00BYXW3230.USD","LU1917777945.USD","IE00BJTD4V19.USD","LU2242649171.HKD","LU0345770993.USD","LU0265550359.USD","LU0106831901.USD","LU2211815571.USD","IE0034235188.USD","LU1261432733.SGD","LU2237443895.HKD","LU0964807845.USD","LU1244550221.USD","GPCR","LU0345769128.USD","LU2264538146.SGD","IE00BDCRKT87.USD","LU0170899867.USD","IE000M9KFDE8.USD","LU2381873111.SGD","LU2417539215.USD","LU0006306889.USD","LU1988902786.USD","LU1974910355.USD","LU0345769631.USD","LU0345770308.USD","IE00BLSP4452.SGD","IE00BJTD4N35.SGD","IE00B1BXHZ80.USD","LU0208291251.USD","SG9999002232.USD","IE00BWXC8680.SGD","LU0820561818.USD","LU2237443382.USD","LU1894683348.USD","LU2357305700.SGD","IE00B775SV38.USD","IE00BZ1G4Q59.USD","LU1032466523.USD"],"gpt_icon":0},{"id":"2602318590","title":"Press Release: Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602318590","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602318590?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:05","pubTimestamp":1767906300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026  -- Septerna, Inc. , a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor  drug discovery, today announced the appointment of Mark A. Wilson as Chief Legal Officer. Mr. Wilson is an accomplished pharmaceutical and biotech executive with more than 25 years of experience across intellectual property, corporate legal, strategic collaborations and corporate governance matters.\"We are thrilled to welcome Mark to the team,\" said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. \"His deep expertise across intellectual property strategy and corporate legal matters will be instrumental as we continue to strengthen our governance framework and maximize the value of our portfolio and proprietary Native Complex Platform. Mark's leadership will be vital as we scale the capabilities needed to execute on our long-term strategy and deliver new medicines for patients.\". \"Septerna represents an ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GPCR","BK4585","BK4599","BK4099","BK4604","TM","BK4555","03160","SEPN","BK4007"],"gpt_icon":0},{"id":"1146401006","title":"Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up 5%; Eli Lilly Rises 4% to Record High; Amgen up 3%; Roche, Novo up Around 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146401006","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146401006?lang=en_us&edition=fundamental","pubTime":"2026-01-07 23:15","pubTimestamp":1767798955,"startTime":"0","endTime":"0","summary":"Weight-loss drugmakers' stocks jumped on Wednesday. Structure Therapeutics up 5%; Eli Lilly rose 4% to record high; Amgen up 3%; Roche, Novo up around 2%.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Weight-Loss Drugmakers' Stocks Jump. Eli Lilly Rises 4% to Record High","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","AMGN","VKTX","RHHBY","GPCR","PFE","NVO"],"gpt_icon":0},{"id":"1123730705","title":"Weight-Loss Drugmakers' Stocks Jump. Arrowhead up over 17%; Structure Therapeutics up over 6%; Novo Nordisk up 5%; Viking, Pfizer, Eli Lilly up Around 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123730705","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123730705?lang=en_us&edition=fundamental","pubTime":"2026-01-06 23:05","pubTimestamp":1767711953,"startTime":"0","endTime":"0","summary":"Weight-loss drugmakers' stocks jumped. Arrowhead up over 17%; Structure Therapeutics up over 6%; Novo Nordisk up 5%; Viking, Pfizer, Eli Lilly up around 2%.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"c7a5ad1f4c9cc897f075885965193731","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","NVO","LLY","RHHBY","VKTX","AMGN","PFE"],"gpt_icon":1},{"id":"2601814858","title":"BRIEF-Structure Therapeutics Inc - Gasherbrum Entered Agreement With Genentech And Roche - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601814858","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601814858?lang=en_us&edition=fundamental","pubTime":"2026-01-06 06:15","pubTimestamp":1767651351,"startTime":"0","endTime":"0","summary":"BRIEF-Structure Therapeutics Inc - Gasherbrum Entered Agreement With Genentech And Roche - SEC FilingStructure Therapeutics Inc GPCR.O:STRUCTURE THERAPEUTICS INC - GASHERBRUM ENTERED AGREEMENT WITH GENENTECH AND ROCHE - SEC FILINGSTRUCTURE THERAPEUTICS INC - GENENTECH TO PAY GASHERBRUM $100 MILLION - SEC FILINGSource text: [ID:n0001104659-26-000620]Further company coverage: GPCR.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2601837879","title":"Structure Therapeutics Inc - Genentech to Pay Gasherbrum $100 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601837879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601837879?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:09","pubTimestamp":1767647379,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60GL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GPCR","BK4599","BK4007"],"gpt_icon":0},{"id":"2601683787","title":"Structure Therapeutics Subsidiary Grants Genentech $100 Million License for GLP-1 Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2601683787","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601683787?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:08","pubTimestamp":1767647295,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc. announced that its wholly-owned subsidiary, Gasherbrum Bio, Inc., has entered into a material agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. Under the agreement, Gasherbrum has granted Genentech and Roche a non-exclusive, sublicensable, royalty-bearing license to certain patents covering a class of oral GLP-1 receptor agonists distinct from aleniglipron. Genentech will make a one-time, non-refundable payment of $100 million to Gasherbrum and will pay royalties at a low single digit rate on net sales of products containing CT-996, a proprietary compound owned by Genentech. The agreement does not affect Structure Therapeutics’ ongoing programs or grant Genentech any patent prosecution or enforcement rights.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL4Rz0qt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4007","GPCR"],"gpt_icon":0},{"id":"2600708537","title":"The Year-End 2025 Biotech Rally And What It Means For 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2600708537","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600708537?lang=en_us&edition=fundamental","pubTime":"2025-12-31 23:54","pubTimestamp":1767196440,"startTime":"0","endTime":"0","summary":"Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and political noise has transformed into one of the market’s standout performers, powered by deal making, drug approvals, and breakthrough clinical results. The big question heading into 2026 is simple: can this momentum last?The performance metrics speak volumes. The iShares Biotechnology ETF  has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF  has done even better with gains around 35.84%. The Nasdaq Biotechnology Index sits at 5,766.59, marking a 34% jump for the year.Regulatory wins provided another boost. The FDA greenlit 44 new therapies in 2025, with 26 approvals coming in the second half alone. December saw notable wins including Cytokinetics Incorporated’s  Myqorzo for a heart condition, marking the company’s first approval after 27 years ","market":"hk","thumbnail":"/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/25/12/49650052/the-year-end-2025-biotech-rally-and-what-it-means-for-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/12/49650052/the-year-end-2025-biotech-rally-and-what-it-means-for-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":[".IXIC","JNJ","SQQQ","LU0471298694.HKD","RNA","PFE","QID","IBB","ITCI","SG9999014880.SGD","NQmain","IE00BBT3K403.USD","BK4505","LU0256863811.USD","PSQ","LU0432979614.USD","BK4581","OMER","TQQQ","LU2430703178.SGD","IE00B1BXHZ80.USD","VRNA","NVIW.SI","GPCR","IE00BVYPNW00.USD","IE0005OL40V9.USD","MRK","NVS","LU2063271972.USD","MNQmain","IE00BJT1NW94.SGD","CYTK","LU0823434740.USD","TSYW.SI","MNPR","LU1037948897.HKD","LU2592432038.USD","QLD","USAW.SI","USJW.SI","LU0306807586.USD","EYPT","LU1116320737.USD","BK4532","LU1935042991.SGD","IONS","LU2089984988.USD","SG9999014906.USD"],"gpt_icon":1},{"id":"2595777995","title":"BUZZ-Structure Therapeutics doubles while other obesity drug developers decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2595777995","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595777995?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:29","pubTimestamp":1767191374,"startTime":"0","endTime":"0","summary":"BUZZ-Structure Therapeutics doubles while other obesity drug developers decline ** Shares of Structure Therapeutics GPCR.O have more than doubled this year, after declining 33% in 2024 ** Structure earlier this month said its experimental oral obesity pill showed 11.3% reduction in weight at 120 mg dose at 36 weeks in mid-stage study** Shares of other obesity drug developers such as Viking Therapeutics VKTX.O and Altimmune ALT.O are set to end in red      ** Weight-loss drug market is surging, with biotech firms racing to win share in sector dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N** Analysts forecast the industry will generate about $150 billion in annual sales in the next decade** Shares of Viking are down 12.2% this year after more than doubling in 2024; company said its experimental weight-loss pill helped patients lose 12.2% of their body weight in mid-stage trial, missing Wall Street's top-end expectations of 15%** Shares of Altimmune have fallen 49.9% this year, se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nL4N3Y10LP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015952.SGD","LU0266013472.USD","LU2023250504.SGD","BK4516","LU2087625088.SGD","IE0009355771.USD","LU1988902786.USD","LU0689472784.USD","LU1366192091.USD","LU2746668461.USD","IE00B1BXHZ80.USD","SG9999014880.SGD","LU0786609619.USD","LU1551013342.USD","LU2471134952.CNY","LU2237443465.HKD","LU1720051017.SGD","LU2360106947.USD","IE00BKDWB100.SGD","LU1548497426.USD","LU2361044865.SGD","SG9999017495.SGD","LU1323610961.USD","LU2106854487.HKD","LU1093756168.USD","IE00BK4W5L77.USD","LU0122379950.USD","LU0820561818.USD","LU0882574055.USD","LU2456880835.USD","IE00B4JS1V06.HKD","LU0094547139.USD","LU1814569148.SGD","SGXZ99366536.SGD","LU0320765992.SGD","IE00BJJMRY28.SGD","LU2491050071.SGD","BK4599","LU0889565916.HKD","LU2552382058.USD","SG9999018865.SGD","LU2361045086.USD","LU2471134523.USD","SG9999001176.SGD","LU1035775433.USD","IE00B7KXQ091.USD","LU1551013425.SGD","LU1868836591.USD","LU0320765059.SGD","LU0672654240.SGD","LU2750360997.AUD","LU0820561909.HKD","IE00BFSS8Q28.SGD","IE00B2B36J28.USD","LU1720051108.HKD","LU2324357040.USD","LU0079474960.USD","LU0289739699.SGD","SG9999014898.SGD","GPCR","LU0006306889.USD","LU2471134796.USD","LU0109391861.USD","SG9999018857.SGD","LU2265009873.SGD","LU1127390331.HKD","IE00BKPKM429.USD","LU0234572021.USD","LU2462157665.USD","LU1280957306.USD","IE00BJLML261.HKD","LU2237438978.USD","LU2264538146.SGD","LU2237443978.SGD","LU0203202063.USD","LU0354030438.USD","LU0316494557.USD","LU2168564149.EUR","LU1712237335.SGD","BK4534","BK4007","LU0823434583.USD","LU1989771016.USD","GB00BDT5M118.USD","LU2168563687.JPY","LU0353189680.USD","LU1232071149.USD","LU1093756325.SGD","LU2236285917.USD","LU1983299246.USD","IE0005OL40V9.USD","LU2237443895.HKD","LU0238689110.USD","LU1878469433.USD","IE0002141913.USD","LU1868836757.USD","SG9999015978.USD","LU0823434740.USD","LU0787776722.HKD","LU1917777945.USD","LU2552382132.HKD","LU0114720955.EUR","LU0058720904.USD","LU2211815571.USD","LU2237443622.USD","LU2491049909.HKD","LU0256863811.USD","LU2361044949.HKD","LU0432979614.USD","LU2602419157.SGD","SGXZ51526630.SGD","LU0683600562.USD","LU0385154629.USD","LU1064131342.USD","LU0354030511.USD","LU2237443382.USD","IE0004445239.USD","LU1868836914.USD","IE00BK4W5M84.HKD","LU1868837300.USD","SG9999015986.USD","LU0471298694.HKD","IE00B1XK9C88.USD","LU2357305700.SGD","LU1804176565.USD","LU1868837136.USD","IE00BJJMRZ35.SGD","IE0004445015.USD","LU1069344957.HKD","IE00B775H168.HKD","LU2112291526.USD","LU2168564222.USD","SG9999013999.USD","LU1291159041.SGD","LU1623119135.USD","LU0708995401.HKD","LU2108987350.USD","LU2461242641.AUD","IE00BJJMRX11.SGD","IE00B4R5TH58.HKD","LU0471298777.SGD","BK4533","SG9999001176.USD","LU0198837287.USD","LU0061475181.USD","LU0353189763.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU0203201768.USD","IE00BWXC8680.SGD","LU0943347566.SGD","LU1974910355.USD","SG9999015945.SGD","LU1267930730.SGD","LU2168564495.EUR","LU2552382215.SGD","LU0323591593.USD","BK4585","BK4581","LU0106261372.USD","IE00BN29S564.USD","LU2471134879.HKD","SG9999014914.USD","SG9999014906.USD","LU2168564065.EUR","LU2491050154.USD","LU0823416689.USD","SGXZ31699556.SGD","BK4139","LU2089984988.USD","SGXZ81514606.USD","LU2468319806.SGD","LU0466842654.USD","LU0097036916.USD","LU0109394709.USD","LU0456855351.SGD","LU2750360641.GBP","IE00BJT1NW94.SGD","IE00BFSS7M15.SGD","LU0096364046.USD","LU1023059063.AUD","LU1057294990.SGD","LU2063271972.USD","LU0882574139.USD","LU0256863902.USD","LU2417539215.USD","BK4588","LU0640476718.USD","LU2237443549.SGD","SGXZ57979304.SGD","LU2746668974.SGD","LU0417517546.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.structuretx.com","stockEarnings":[{"period":"1week","weight":0.2729},{"period":"1month","weight":0.3014},{"period":"3month","weight":2.0599},{"period":"6month","weight":3.3808},{"period":"1year","weight":2.3227},{"period":"ytd","weight":0.2125}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.129255},{"month":2,"riseRate":0,"avgChangeRate":-0.138732},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.094654},{"month":4,"riseRate":0.666667,"avgChangeRate":0.182978},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.022859},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133478},{"month":7,"riseRate":0,"avgChangeRate":-0.101218},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.04351},{"month":9,"riseRate":1,"avgChangeRate":0.463472},{"month":10,"riseRate":0.666667,"avgChangeRate":0.200398},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.123384},{"month":12,"riseRate":0.333333,"avgChangeRate":0.164068}],"exchange":"NASDAQ","name":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","nameEN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD,GPCR,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎国际,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股价,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股市,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票价格,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票交易,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票购买,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction